1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

SNAP

Discussion in 'KCI' started by anonymous, Oct 25, 2018 at 10:22 PM.

  1. anonymous

    anonymous Guest

    SNAP is a decent product IF your patient has a small enough wound and is semi intelligent and can handle looking at it every few hours to make sure the green line isn’t red and is a compliant patient that has a home health that can work with it at all hours of the day and night . I hated working for this company and working with my micromanager and bs conference calls about a crap product that has no actual number attached to it.